drug · small molecule
mavorixafor
Marketedupdated 3mo agoby $XFOR X4 Pharmaceuticals, Inc🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for neoplasm and 10 investigational indications.
targets
C-X-C chemokine receptor type 4
all catalysts(0)
nothing on the calendar yet
Trials studying mavorixafor
- phase1A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function
- phase3A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
- phase2A Study of Mavorixafor in Participants With Congenital Neutropenia and Chronic Idiopathic Neutropenia Disorders
- phase3Efficacy and Safety Study of Mavorixafor in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
- phase1Drug-Drug Interaction Potential of Mavorixafor
- phase1A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4
Patent cliff
source: FDA Orange Bookfirst barrier falls
Apr 26, 2029
~2.7 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (6)
- Dec 11, 2038formulationUS 10548889
- Dec 11, 2038formulationUS 11045461
- Dec 11, 2038formulationUS 12115156
- Dec 22, 2036method-of-use (U-3932)US 10610527
- Dec 22, 2036method-of-use (U-3932)US 11219621
- Dec 14, 2036formulationUS 10953003
FDA exclusivities (2)
- Apr 26, 2031ODE-480Orphan Drug (7y)4.7y
- Apr 26, 2029NCENew Chemical Entity (5y)2.7y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that